

ImmuPharma PLC

15:30 25 Feb 2019

ImmuPharma continues to build data package for flagship lupus treatment

- Flagship drug is Lupuzor - a treatment for lupus
- Results from follow-up study due within next few months
- Nucant cancer treatment also going through the clinic
- Ureka subsidiary being divested

What it does

ImmuPharma PLC (LON:IMM) specialises in developing drugs for serious medical conditions for which there is a distinct lack of existing treatments.

Its flagship drug is called Lupuzor - a treatment for the autoimmune disease lupus.

The drug missed its primary endpoint in a phase II study last year, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

The results certainly haven't held back ImmuPharma or its top drug. In fact, boss Tim McCarthy has said that Lupuzor still possesses "blockbuster potential", meaning it could rack more than US\$1bn in annual sales.

After the end of the phase III trial, 62 patients took part in a 'follow-up' study - called an open-label extension study. Results from this are expected between April and June.

On top of that, another 500 lupus sufferers are being given access to Lupuzor for the next two years as part of a managed access programme.

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

Blue sky

In the immediate future, results from the Lupuzor follow-up study are due by the end of June, while the managed access programme is set to complete towards the end of 2020.

Should Lupuzor prove itself in those two tests, ImmuPharma will use the data to try to get full regulatory approval the drug, something bosses hope to achieve "in the medium term".


Lupuzor isn't ImmuPharma's only drug going through the clinic. Its Nucant cancer treatment has yielded "promising results" in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mIn stake.

Price: 11.79p

Market Cap: £16.44M

1 Year Share Price Graph



June 2018 December 2018 June 2019

Share Information

Code: IMM

Listing: AIM

52 week **High** **Low**
24.40p 8.50p

Sector: Pharma & Biotech

Website: www.immupharma.co.uk

Company Synopsis:

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

A licence agreement between the two is expected to be signed by the end of March, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma has said.

What the boss is saying

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.